Cholesteatoma Secondary to Temporal Bone Involvement by Langerhans Cell Histiocytosis
Gilles Roger(Inserm), Jean Donadieu(Sorbonne Université), P. Bordure(Centre Hospitalier Universitaire de Nantes), Caroline Thomas(Centre Hospitalier Universitaire de Nantes), Benoît Godey(Hôpital Pontchaillou), Virginie Gandemer, Éréa-Noël Garabédian(Inserm), Nicolas Leboulanger(Hôpital Necker-Enfants Malades), Marie Dupré(Sorbonne Université)
Cited by 13
Related Papers
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
|Blood|2016|1.6k
Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies
|Journal of Allergy and Clinical Immunology|2017|316
Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma
|International Journal of Pediatric Otorhinolaryngology|2009|235
The Severe Chronic Neutropenia International Registry: 10-Year Follow-up Report
|Supportive Cancer Therapy|2006|166
Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30‐year nationwide cohort of 1478 patients under 18 years of age
|British Journal of Haematology|2016|130